Our Anti-OTP for diagnostics and classification of lung cancer
December 2022 (Department of Pathology GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands)
The results of our co-development project with the Department of Pathology, Maastricht University, using our Anti-OTP monoclonal antibodies on lung cancer tissue, have now been published in the Translational Lung Cancer Research journal!
Orthopedia homeobox (OTP) has shown to be a useful prognostic marker to predict the outcome of pulmonary carcinoids, which the World Health Organization also supports. However, the discontinuation of the initially used polyclonal antibody and the absence of a reliable, routinely applicable monoclonal OTP antibody hampers implementation in routine diagnostics.
Thanks to our co-development program, new monoclonal antibodies directed against OTP were developed and verified on formalin-fixed paraffin-embedded tissue of pulmonary neuroendocrine tumors (NETs) for clinical diagnostics.
We are confident that these novel monoclonal antibodies will improve routine diagnostics and current classification in the field of lung pathology.
Read more about our co-development program.
PrecisA Monoclonals™ are in-house developed mouse monoclonal antibodies for dedicated targets. The antibodies are validated for use in IHC, WB and ICC-IF.